Srinivas Vengala
Interventional Cardiology · Hot Springs, ARNPI 1710032008
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,849 of the $17,892 with a category attached, or 66.2%. 32 manufacturers reported payments, led by Medtronic at 60.0% of the total. Reporting peaked in 2024 at $9,597 and has fallen 89.1% since, to $1,043 in 2025.
Across 302 payments — averaging $59.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Boston Scientific$2K
- Amgen$616
- Novartis$579
- Biotronik Inc.$401
- Abiomed$364
- plus $3K from 26 others
What the payments were for
- Travel & lodging$11,84966%
- Food & beverage$6,02634%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 49 | $10,726 |
| Boston Scientific | 20 | $2,490 |
| Amgen | 31 | $616 |
| Novartis | 44 | $579 |
| Biotronik Inc. | 14 | $401 |
| Abiomed | 5 | $364 |
| Shockwave Medical, Inc | 6 | $351 |
| Johnson & Johnson | 23 | $309 |
| Novo Nordisk | 11 | $263 |
| AstraZeneca | 12 | $231 |
| Pfizer | 15 | $221 |
| E.r. Squibb & Sons, L.L.C. | 11 | $181 |
| Sanofi-aventis U.S. LLC | 12 | $177 |
| Philips North America LLC | 9 | $147 |
| UCB, Inc. | 1 | $147 |
| Irhythm Technologies, Inc. | 7 | $118 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $95 |
| Terumo Medical Corporation | 1 | $78 |
| Gilead | 6 | $76 |
| Boehringer Ingelheim | 3 | $62 |
| Baxter Healthcare | 2 | $53 |
| Inari Medical, Inc. | 1 | $28 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Abbott | 1 | $25 |
| Merck | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Atricure, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
| Sirtex Medical Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,892 in reported general payments places this provider in the 80th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 568 | $440,368 |
| XareltoRivaroxaban | 129 | $111,427 |
| EntrestoSacubitril/Valsartan | 74 | $59,003 |
| BrilintaTicagrelor | 84 | $40,839 |
| Repatha SureclickEvolocumab | 48 | $35,855 |
| FarxigaDapagliflozin Propanediol | 19 | $16,614 |
| Praluent PenAlirocumab | 22 | $16,557 |
| MultaqDronedarone Hcl | 15 | $14,947 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $5,062 |
| Propafenone Hcl ErPropafenone Hcl | 13 | $4,664 |
| Propafenone Hcl | 147 | $4,219 |
| Atorvastatin Calcium | 522 | $3,319 |
| Carvedilol | 527 | $3,114 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 243 | $2,487 |
| Verapamil SrVerapamil Hcl | 12 | $2,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $221 | $440,368568 claims |
| Johnson & JohnsonXarelto | $309 | $111,427129 claims |
| NovartisEntresto | $579 | $59,00374 claims |
| AstraZenecaBrilinta, Farxiga | $231 | $57,454103 claims |
| Sanofi-aventis U.S. LLCMultaq | $177 | $14,94715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Hot Springs
- Jason PeltonHot Springs$8K
- Yuba AcharyaHot Springs$7K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Lena AwarJonesboro$43K
- Zubair AhmedFayetteville$36K
- Stephen BroughtonLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.